Towards New Therapies for Parkinson's Disease
Parkinson's disease (PD) is characterised clinically by various non-motor and progressive motor symptoms, pathologically by loss of dopamine producing cells and intraneuronal cytoplasmic inclusions composed primarily of ?-synuclein. By the time a patient first presents with symptoms of Parkinso...
Kaydedildi:
| Diğer Yazarlar: | |
|---|---|
| Materyal Türü: | Elektronik Kitap Bölümü |
| Dil: | İngilizce |
| Baskı/Yayın Bilgisi: |
IntechOpen
2011
|
| Konular: | |
| Online Erişim: | DOAB: download the publication DOAB: description of the publication |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|
MARC
| LEADER | 00000naaaa2200000uu 4500 | ||
|---|---|---|---|
| 001 | doab_20_500_12854_65253 | ||
| 005 | 20210420 | ||
| 003 | oapen | ||
| 006 | m o d | ||
| 007 | cr|mn|---annan | ||
| 008 | 20210420s2011 xx |||||o ||| 0|eng d | ||
| 020 | |a 954 | ||
| 020 | |a 9789533074634 | ||
| 020 | |a 9789535165453 | ||
| 040 | |a oapen |c oapen | ||
| 024 | 7 | |a 10.5772/954 |c doi | |
| 041 | 0 | |a eng | |
| 042 | |a dc | ||
| 072 | 7 | |a JMM |2 bicssc | |
| 100 | 1 | |a Finkelstein, David I. |4 edt | |
| 700 | 1 | |a Finkelstein, David I. |4 oth | |
| 245 | 1 | 0 | |a Towards New Therapies for Parkinson's Disease |
| 260 | |b IntechOpen |c 2011 | ||
| 300 | |a 1 electronic resource (410 p.) | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 506 | 0 | |a Open Access |2 star |f Unrestricted online access | |
| 520 | |a Parkinson's disease (PD) is characterised clinically by various non-motor and progressive motor symptoms, pathologically by loss of dopamine producing cells and intraneuronal cytoplasmic inclusions composed primarily of ?-synuclein. By the time a patient first presents with symptoms of Parkinson's disease at the clinic, a significant proportion of the cells in the substantia nigra have already been destroyed. This degeneration progresses despite the current therapies until the cell loss is so great that the quality of normal life is compromised. The dopamine precursor levodopa is the most valuable drug currently available for the treatment of PD. However for most PD patients, the optimal clinical benefit from levodopa decreases around five to six years of treatment. The aim of the chapters of this book is to work towards an understanding in the mechanisms of degeneration and to develop disease modifying therapies. | ||
| 540 | |a Creative Commons |f https://creativecommons.org/licenses/by/3.0/ |2 cc |4 https://creativecommons.org/licenses/by/3.0/ | ||
| 546 | |a English | ||
| 650 | 7 | |a Physiological & neuro-psychology, biopsychology |2 bicssc | |
| 653 | |a Physiological & neuro-psychology, biopsychology | ||
| 856 | 4 | 0 | |a www.oapen.org |u https://mts.intechopen.com/storage/books/437/authors_book/authors_book.pdf |7 0 |z DOAB: download the publication |
| 856 | 4 | 0 | |a www.oapen.org |u https://directory.doabooks.org/handle/20.500.12854/65253 |7 0 |z DOAB: description of the publication |